No Data
No Data
Zhaoke Ophthalmology Shrinks Loss in 2023
Zhaoke Ophthalmology (HKG:6622) recorded a decline in attributable loss for the year ended Dec. 31, 2023, to 385 million yuan from 407.3 million yuan in 2022, according to the company's annual report
兆科眼科-B:2023 年報
Zhaoke Ophthalmology-B (06622): Chen Yu resigns as non-executive director
Zhaoke Ophthalmology-B (06622) announced that Chen Yu has resigned as a non-executive director to spend more time on other work arrangements...
Annual Report Observation: The second low-concentration atropine produced in China is coming, and the value of Zhaoke Ophthalmology-B (6622.HK) has been rediscovered
The innovative ophthalmology drug market has always been one of the hot areas that the market has paid great attention to, especially in the field of myopic ophthalmology.
Zhaoke Ophthalmological-B (06622.HK) announces annual results, first confirmation that sales revenue is continuing to expand its footprint globally
Gelonghui, March 27 | Zhaoke Ophthalmology-B (06622.HK) announced that the company first confirmed sales revenue in 2023: in 2023, the company recorded total revenue of RMB 18.8 million, of which RMB 4.7 million came from the sale of ophthalmic drugs (including bemesol timolol and Ruibault), while RMB 8.4 million came from the sale of non-prescription ophthalmic products (Baudexi series hot eye masks). Additionally, the company recorded revenue of RMB 5.6 million from distribution transaction payments outside of China. The company's pipeline is equipped with a variety of key innovative drugs that may have significant curative effects, which can be expected in the future
Zhaoke Ophthalmology-B (06622) announced annual results, net loss of 385 million yuan, a year-on-year decrease of 5.5%
Zhaoke Ophthalmology-B (06622) announced results for the year ended December 31, 2023, and the group achieved revenue...
No Data